Received Oct 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLUBLOK) | SANOFI PASTEUR | UNK | — | OT |
| FLU3 | INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE) | SANOFI PASTEUR | UNK | U8823BA | OT |
received flublok when they were supposed to receive fluzone hd with no reported ae; Initial information received on 29-Sep-2025 regarding an unsolicited valid non-serious case received from a consumer/non-hcp. This case involves an unknown age male patient who received Influenza Quadrivalent Recombinant Vaccine [Flublok] when they were supposed to receive Influenza Usp Trival A-B High Dose Subvirion Vaccine [Fluzone HD] with no reported ae. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose of suspect Influenza Usp Trival A-B High Dose Subvirion Vaccine; Suspension for injection in pre-filled syringe (lot U8823BA with unknown strength, dosage and expiry date) via unknown route for Influenza and received a dose of suspect Influenza Quadrivalent Recombinant Vaccine with unknown (lot number, formulation, strength and expiry date) via unknown route in unknown administration site for Prophylactic vaccination (Immunisation) with no reported ae (wrong product administered) (unknown latency) (unknown latency). There will be no information on batch number and expiration date corresponding to the one at time of event occurrence. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error. No follow-up is possible as Reporter cannot be contacted by Sanofi.